Stocktoria
Oruka Therapeutics, Inc. ORKA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2000-07-21
Oruka Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| R&D expense | $100.6M | $1.0M | $4.7M | $13.8M | $5.0M |
| Operating income | -$122.1M | -$7.3M | -$10.6M | -$19.3M | -$9.8M |
| Interest expense | — | — | — | — | $9,000 |
| Income tax | — | $0 | $0 | $0 | -$9,000 |
| Net income | -$105.4M | -$5.3M | -$9.9M | -$19.3M | -$9.7M |
| EPS (diluted) | — | $-0.37 | $-0.69 | $-1.39 | — |
| Operating cash flow | -$88.2M | -$5.0M | -$10.9M | -$18.8M | -$7.7M |
| Free cash flow | -$88.4M | -$5.0M | -$10.9M | -$18.8M | -$7.7M |
| Cash & equivalents | $46.9M | $37.4M | $42.4M | $53.4M | $49.1M |
| Total assets | $488.6M | $37.9M | $43.1M | $54.9M | $50.4M |
| Total liabilities | $16.7M | $841,000 | $1.4M | $3.9M | $3.9M |
| Shareholders' equity | $471.9M | $37.0M | $41.7M | $51.0M | $46.5M |
Source: SEC EDGAR filings · CIK 0000907654 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.